Serotonin (5-hydroxytryptamine, 5-HT) as well as noradrenaline (NA) are key modulators of various fundamental brain functions including the control of appetite. While manipulations that alter brain serotoninergic signaling clearly affect body weight, studies implicating 5-HT transporters and NA transporters (5-HTT and NAT, respectively) as a main drug treatment target for human obesity have not been conclusive. The aim of this positron emission tomography (PET) study was to investigate how these central transporters are associated with changes of body weight after 6 months of dietary intervention or Roux-en-Y gastric bypass (RYGB) surgery in order to assess whether 5-HTT as well as NAT availability can predict weight loss and consequently treatment success.
View Article and Find Full Text PDFContrary to a widespread impression, dependence is not rare among the elderly. The numbers are clearly increasing. The results of therapy are more favorable than is usually assumed, especially when it is possible to form groups appropriate to the age which cope with the particular problems of this stage of life better than mixed age groups.
View Article and Find Full Text PDF